2026年2月10日至13日，全球检验医学领域的重要盛会——WHX Labs Dubai 2026（原中东医疗实验室展Medlab Middle East）在迪拜世界贸易中心举行。
珠海市银科医学工程股份有限公司（以下简称“银科医学”）以“直对方案提供商”的全新姿态参展，集中展示了从培养、药敏到分子诊断的全流程分枝杆菌检测产品体系，获得国际客商高度关注。
本届展会吸引来自40多个国家的800余家企业参展。银科医学重点展出的YK AIMT系列全自动分枝杆菌培养监测仪及配套分枝杆菌液体培养管，凭借智能化设计与高效检测能力，成为现场焦点。该系列包含YK-320、YK-640、YK-960、YK-1280、YK-1600、YK-1920六款型，采用模块化堆叠设计，单模块支持320孔位，最高可扩展至1920孔位。设备集成扫码配位、免拖自启、24小时智能值守等功能，培养曲线可实时同步至手机端，大幅降低人工操作门槛，助力实验室实现远程监控与自动化管理。
更值得关注的是，银科医学首次完整呈现其“直对方案”——一套由自主产品线贯通样本接种、培养监测、菌种鉴定到耐药检测的全流程解决方案。该方案核心MycoDirect DST药敏检测板覆盖26种一线及二线抗结核药物，并与培养系统无缝衔接，阳性样本可直接进入药敏流程，最快11天即可完成从培养到药敏的全过程，将传统数周的报告周期大幅缩短。尤其针对贝达喹啉（Bdq）、德拉马尼（Dlm）、吡嗪酰胺（PZA）等新型耐药监测药物，方案填补了新兴市场国家在新药药敏领域的技术空白。
在分子诊断层面，银科医学同步展出了基于荧光PCR熔解曲线法的结核分枝杆菌耐药基因突变检测试剂盒及NTM鉴定试剂盒，为快速筛查耐药突变和非结核分枝杆菌感染提供精准工具。同时，YK-FIA200免疫荧光定量分析仪及其配套试剂进一步拓展了实验室在结核之外的综合检测能力，满足多元化临床需求。
展会期间，银科医学展台持续保持高热度。来自巴基斯坦、埃及、印尼、尼日利亚等结核高负担国家的实验室采购代表在现场完成详细交流。一位沙特客户针对YK AIMT系列的LIS对接能力及MycoDirect药敏板的CE认证进行了长达45分钟的深度交流；尼日利亚国家结核与麻风控制项目实验室主任则现场索取液体培养管稳定性验证报告。三天展期，银科展台累计接待专业访客超过200人次，其中绝大多数围绕“直对方案”展开技术探讨。
此次亮相WHX Labs Dubai 2026，标志着银科医学从单一诊断产品出口向系统化解决方案输出的战略升级。通过持续创新与流程整合，银科医学正致力于让全球实验室——尤其是结核高负担地区的医疗机构——拥有更高效、更自主、可持续的结核诊断能力。
From February 10 to 13, 2026, WHX Labs Dubai 2026 (formerly Medlab Middle East), a premier global event in laboratory medicine, was held at the Dubai World Trade Centre. Zhuhai ENCODE Medical Engineering Co., Ltd. (hereinafter referred to as "ENCODE") made a strong appearance with its new positioning as a "Direct Solution Provider," showcasing a comprehensive product portfolio covering the entire mycobacteria testing workflow - from culture and drug susceptibility testing (DST) to molecular diagnostics - garnering significant attention from international buyers.
The exhibition attracted over 800 companies from more than 40 countries. ENCODE's featured exhibits, the YK AIMT Series Automated Mycobacteria Culture Monitoring Systems and supporting Mycobacteria Liquid Culture Tubes, became focal points due to their intelligent design and efficient detection capabilities. The series includes six models (YK-320, YK-640, YK-960, YK-1280, YK-1600, and YK-1920) featuring a modular stackable design, with each module supporting 320 wells and scalability up to 1920 wells. Integrated functions such as barcode-based well assignment, automatic start-up, and 24/7 intelligent monitoring enable real-time culture curve synchronization to mobile devices, significantly reducing manual intervention and empowering laboratories with remote monitoring and automated management.
Notably, ENCODE unveiled its complete "Direct Solution" for the first time - an end-to-end workflow connecting sample inoculation, culture monitoring, species identification, and drug resistance testing, all powered by ENCODE's proprietary product line. The core of this solution, the MycoDirect DST Susceptibility Plate, covers 26 first-line and second-line anti-tuberculosis drugs. Seamlessly integrated with the culture system, positive samples can directly proceed to DST, enabling a turnaround time from culture to DST results in as little as 11 days - a dramatic reduction from the conventional multi-week process. Crucially, the solution incorporates new anti-tuberculosis drugs like Bedaquiline (Bdq), Delamanid (Dlm), and Pyrazinamide (PZA) into its susceptibility testing panel, addressing a critical gap in new drug DST accessibility in emerging market countries.
On the molecular diagnostics front, ENCODE also presented its Tuberculosis Drug Resistance Gene Mutation Detection Kit and NTM Identification Kit (both utilizing Fluorescent PCR Melting Curve Analysis), providing precise tools for rapid screening of drug resistance mutations and non-tuberculous mycobacteria infections. Additionally, the YK-FIA200 Immunofluorescence Analyzer and its supporting reagents expand the laboratory's comprehensive testing capabilities beyond tuberculosis, catering to diverse clinical needs.
Throughout the exhibition, ENCODE's booth maintained a consistently high level of engagement. Laboratory procurement representatives from tuberculosis high-burden countries including Pakistan, Egypt, Indonesia, and Nigeria conducted detailed discussions on-site. A client from Saudi Arabia engaged in a 45-minute in-depth conversation regarding the LIS interface capabilities of the YK AIMT Series and the CE certification scope of the MycoDirect DST Plate. The Director of the National Tuberculosis and Leprosy Control Program Laboratory from Nigeria requested an electronic version of the stability validation report for the liquid culture tubes. Over the three-day event, the ENCODE booth received more than 200 professional visitors, with the vast majority engaging in technical discussions centered around the "Direct Solution."
This appearance at WHX Labs Dubai 2026 marks a strategic upgrade for ENCODE, transitioning from exporting individual diagnostic products to providing integrated systematic solutions. Through continuous innovation and workflow integration, ENCODE is dedicated to empowering laboratories worldwide - especially healthcare institutions in tuberculosis high-burden regions - with more efficient, autonomous, and sustainable tuberculosis diagnostic capabilities.
